NEW YORK (GenomeWeb) – GATC Biotech today announced it has signed a worldwide commercial agreement with Molecular Health.
Under the terms of the agreement, GATC Biotech will market and support Molecular Health's TreatmentMap tumor profiling system, which includes a next-generation sequencing-based test which looks at 500 cancer-linked genes to guide treatment strategies. Molecular Health has launched TreatmentMap in the US and in Germany and GATC Biotech will work with the company to increase adoption of the technology.
"This sales and marketing agreement with GATC Biotech has significantly enhanced our prospects of exploiting TreatmentMap's definitive market potential," Molecular Health CEO Lutz Voelker said in a statement. In January 2014, the companies announced a deal for GATC Biotech to provide its laboratory management system in Molecular Health's clinical lab.
Based in Heidelberg, Germany, with US presence in The Woodlands, Texas and Cambridge, Mass., Molecular Health announced in March 2014 that its US, Illumina-equipped, clinical laboratory received CLIA certification.
Konstanz, Germany-based GATC Biotech provides DNA and RNA sequencing services. Last month, it announced it would be the exclusive supplier of Qiagen's Ingenuity Variant Analysis NGS data analysis solution